It is not yet known what schedule of PrEP dosing will be most effective, nor what level of adherence will be required for maximum tolerability and efficacy.
Maximum tolerability was defined as the point when excessive toxicities warranted stopping FOLFIRINOX, even if a patient had not achieved their maximum response.
38 They also demonstrate fewer hypoglycemic events than rapid-acting analogs and premixed formulations, which will be discussed in the following sections, and therefore offer maximum tolerability among the insulin regimens.
To determine the safety, tolerability, maximum tolerated dose, and bioactivity of an intravitreal injection of vascular endothelial growth factor (VEGF) Trap-Eye, a fusion protein of binding domains from human VEGF receptors 1 and 2 with human immunoglobulin-G Fc that binds VEGF family members, in patients with neovascular age-related macular degeneration (AMD).
This phase 1 study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics and preliminary activity of intravenous (IV) ixazomib in relapsed/refractory lymphoma patients who had received ⩾2 prior therapies.
This phase Ib trial assessed safety, tolerability, and maximum tolerated dose (MTD) of figitumumab (CP-751,871), a fully human monoclonal antibody targeting the insulin-like growth factor type 1 receptor (IGF-IR), in combination with docetaxel.
The primary objectives of the present study were to determine the safety, tolerability and maximum tolerated dose (MTD) of daily oral erlotinib in combination with 3-week cycles of docetaxel/carboplatin as first-line treatment for patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
The present phase I study was designed to evaluate the tolerability and maximum tolerated dose (MTD) of a 20-min, 24-h and 5-day infusion of patupilone every 3 weeks, together with prophylactic nutritional supplementation and active diarrhoea management in patients with pretreated mCRC.
The aim of this Phase I study was to establish the safety, tolerability, preliminary efficacy, maximum tolerated dose (MTD) and schedule of EZN-4176 in men with progressive CRPC.
Oral doses of ZD4054 evaluated were 2.5, 10, 20, 30, 60, 120, 150 and 240 mg, with dose escalation continued based on tolerability until the maximum tolerated dose had been defined.
The aim of this study was to determine tolerability, toxicities, the maximum tolerated dose (MTD) based upon predetermined dose limiting toxicities (DLT) and the recommended phase II dose of OM-174 administered as a 15 minutes intravenous infusion, repeated twice weekly for 5, 10 or 15 administrations.
